conferenceseries.com

11th world congress on

VIROLOGY AND INFECTIOUS DISEASES

May 17-18, 2018 Tokyo, Japan



Gilbert Glady

European Bio Immune(G)ene Medicine Association, France

BI(G)MED -Bio Immune(G)ene medicine as an innovative nanotherapeutical immunotherapy of chronic viral reactivations related to EBV

The term viral reactivation is far from being widely accepted by the scientific community perhaps this is due to an initial semantic misunderstanding of the notions of infection and reactivation, the second not being a particular form of the first, but something very different coming under a permanent but somehow restrained conflict existing between a latent and recurrent virus and the immune system. EBV is among all viruses the one where the concept of reactivation applies the best, with its genome being of consistent size and very adaptive, able to modulate various types of latency, to mimic the immune reactions engaged against him, to integrate into cellular DNA to control it and ultimately immortalize the carrying cell. This viral reactivation, expression of a conflict whose outcome will long remain uncertain, will be able to generate a large number of pathological disorders, ranging from a banal chronic fatigue syndrome to malignancies, to a large number of auto-immune diseases. Once the biological diagnosis has been made, it is important to implement a treatment capable of neutralizing the aggressor and preventing it from initiating the pathophysiological processes responsible for the mentioned above disorders. This possibility exists today by resorting to a therapy using ultra low doses of various types of immunocompetent molecules, but also of epigenetic regulators such as non-coding RNAs being of viral origin or belonging to the host cell. Some clinical examples make it possible to better specify the therapeutic procedure used and to emphasize its biological effectiveness.

Biography

Gilbert Glady has expertise in immunology and immunogenetics and has also developed interest for alternative medicines that leaded him to nanomedicine and nanobiotechnology. He thus became in 2010 the Creator of the BI(G)MED method (Bio Immune(G)ene Medicine) and Director of EBMA, the European association for training the medical profession in BI(G)MED. He has participated in numerous international congresses in the field of immuno-allergology, infectiology and oncology with posters and oral presentations.

info@ebma-europe.com

Notes: